天演藥業 ADAG 深 滬
等待開盤 03-26 09:30:00 美东时间
4.07
+0.460
+12.74%
華盛通- 最 高4.18
- 今 開3.67
- 成交量 16.03万股
- 最 低 3.67
- 昨 收 3.61
- 總市值 1.92亿
- 52周最高 4.5791
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 1.30
- 委 比 -11.89%
- 總股本 4713.13万
- 歷史最高 31.83
- 量 比 1.45
- 振 幅 14.13%
- 歷史最低 0.90
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Adagene Inc. announced that muzastotug (ADG126) will be highlighted in two poster presentations at the AACR 2026 Meeting. The first presentation evaluates muzastotug in combination with pembrolizumab and fruquintinib for advanced colorectal cancer, while the second focuses on its combination arm in hepatocellular carcinoma. Adagene specializes in antibody-based cancer therapies, utilizing its proprietary SAFEbody technology to enhance safety and ...
03-17 20:35
Palvella Therapeutics launches $150M public stock offering
Palvella Therapeutics (PVLA) announced the commencement of an underwritten public offering of $150M of its common stock. The company expects to grant underwriters a 30-day option to purchase up to an ...
02-25 05:21
Palvella surges on late-stage trial win for lead asset
Shares of Palvella Therapeutics (PVLA) rose more than 30% on Tuesday after the company announced that a late-stage trial for its lead asset, Qtorin rapamycin, reached its main goals, paving the way fo...
02-25 00:27
天演药业公布2026年临床数据公布与研发进展计划
经济观察网 天演药业公布了2026年的业务进展及年度目标，包括多项临床数据公布与研发计划。 近期事件 2026年第一季度：计划公布muzastotug（ADG...
02-18 00:47
Adagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. announces that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (virtual on Feb. 25, 2026) and the Leerink Global Healthcare Conference (Miami, Mar. 8-11, 2026). Webcasts will be available on the Company’s website. Adagene focuses on advancing antibody-based cancer immunotherapies using innovative platforms like SA...
02-17 14:27
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Tyra Bioscience (TYRA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
02-15 02:20
Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to
01-23 21:21
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. reported unaudited cash of $74.5M as of Dec 31, 2025, providing runway into late 2027. Key 2025 achievements include Phase 1b/2 trial results for muzastotug in MSS CRC, FDA Fast Track designation for muzastotug + pembrolizumab, regulatory alignment with FDA, and initiation of a randomized Phase 2 trial. Strategic partnerships with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio advanced masked antibody therapies. 2026 objectives in...
01-23 13:00
